Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon in Huntington's Disease
NCT00387270Phase 2Completed
- Sponsor
- Medivation
- Start
- Oct 2006
- Primary completion
- Mar 2007
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of latrepirdine in Huntington's disease (HD), sponsored by Medivation. Primary endpoint: Dose-limiting toxicities at 7 days. Started Oct 2006; status: completed.
02
Drugs
latrepirdine
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT00387270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387270.